Clinical trials: Erosive Esophagitis
Erosive Esophagitis
Treatment Effect According to Timing of Administration of DWP14012 40 mg
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
- Trial name
- NCT04613895
- Testing
- DWP14012
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Esophagitis
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE.
- Trial name
- NCT05587309
- Testing
- BLI5100, PPI Control
- Where
- 122 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- Braintree Laboratories
Erosive Esophagitis
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02615184
- Testing
- Dexlansoprazole
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 24 people
- Sponsor
- Takeda
Gastroesophageal; Reflux With Esophagitis, Gastroesophageal Reflux
Study of Dietary Patterns and Food Diversity in Russian GERD Patients
The aim of the study is to assess food diversity and dietary patterns in Russian GERD patients
- Conditions
- Gastroesophageal; Reflux With Esophagitis, Gastroesophageal Reflux, GERD, Heartburn
- Trial name
- NCT04252144
- Testing
- Dietary assessment
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Russian Academy of Medical Sciences
Gastroesophageal Reflux Disease (GERD), Heartburn
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Trial name
- NCT01129713
- Testing
- Secretol, Nexium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Effexus Pharmaceutical
Gastroesophageal Reflux Disease With Esophagitis
PPI Dosing Per CYP2C19 Genotype
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication…
- Trial name
- NCT07843264
- Testing
- CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Florida
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
Erosive Esophagitis
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
- Trial name
- NCT02388724
- Testing
- Vonoprazan, Lansoprazole
- Where
- 64 sites in China, Malaysia and 2 more
- Volunteers
- 481 people
- Sponsor
- Takeda
Erosive Esophagitis, GERD
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.
- Trial name
- NCT02028663
- Testing
- CJ-12420, Esomeprazole
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- HK inno.N Corporation
Esophagitis, Reflux
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.
- Trial name
- NCT00175045
- Testing
- Lansoprazole
- Volunteers
- 68 people
- Sponsor
- Takeda
Barrett Esophagus, Proton Pump Inhibitor
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
On-demand PPI therapy is feasible for the long-term treatment of patients with Barrett's esophagus.
- Conditions
- Barrett Esophagus, Proton Pump Inhibitor, Symptom, Reflux
- Trial name
- NCT04329000
- Testing
- Esomeprazole 40mg, Esomeprazole
- Volunteers
- 218 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Erosive Esophagitis
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI)…
- Trial name
- NCT02388737
- Testing
- Vonoprazan, Lansoprazole
- Where
- 72 sites in China, Malaysia and 2 more
- Volunteers
- 703 people
- Sponsor
- Takeda
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole…
- Trial name
- NCT07313774
- Testing
- Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose
- Sponsor
- Cinclus Pharma Holding AB
GERD
Sopran - Omeprazole Treatment Versus Surgery
The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment
- Trial name
- NCT00256737
- Testing
- Omeprazole
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease, Erosive Esophagitis
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
- Trial name
- NCT05890001
- Testing
- BLI5100
- Where
- 60 sites in United States
- Volunteers
- 400 people
- Sponsor
- Braintree Laboratories
Esophagitis, Reflux
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification…
- Trial name
- NCT02463643
- Testing
- Z-215 10mg, Z-215 20mg, Rabeprazole Sodium
- Where
- Japan
- Volunteers
- 503 people
- Sponsor
- Zeria Pharmaceutical